Sanchez CG, et al. - Here, analysts figure out if nelfinavir mesylate (NFV), a drug approved by the Food and Drug Administration (FDA) for treating HIV infection can be repurposed to treat pulmonary fibrosis in systemic scleroderma (SSc). NFV abrogates TGF-β1–mediated fibroblast to myofibroblast differentiation (FMD) and pulmonary fibrosis through off-target protein binding and supports consideration of this FDA-approved medication as an anti-fibrotic agent.